These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37946492)

  • 41. A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis.
    Gao J; Feng L; Li Y; Lowe S; Guo Z; Bentley R; Xie C; Wu B; Xie P; Xia W; Ma S; Liu H; Guo X; Uy JPN; Zhou Q; Wazir H; Sun C
    Am J Prev Med; 2023 Feb; 64(2):275-284. PubMed ID: 36266115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting.
    Yap J; Tham MY; Poh J; Toh D; Chan CL; Lim TW; Lim SL; Chia YW; Lim YT; Choo J; Ding ZP; Foo LL; Kuo S; Lau YH; Lee A; Yeo KK
    Ann Acad Med Singap; 2022 Feb; 51(2):96-100. PubMed ID: 35224605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study.
    Park H; Yun KW; Kim KR; Song SH; Ahn B; Kim DR; Kim GB; Huh J; Choi EH; Kim YJ
    J Korean Med Sci; 2021 Aug; 36(32):e232. PubMed ID: 34402230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular Safety of COVID-19 Vaccination in Patients With Cancer: A Self-Controlled Case Series Study in Korea.
    Ryu JH; Choi A; Woo J; Lee H; Kim J; Yoo J; Shin JY
    J Korean Med Sci; 2024 Jun; 39(24):e190. PubMed ID: 38915282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
    Funk PR; Yogurtcu ON; Forshee RA; Anderson SA; Marks PW; Yang H
    Vaccine; 2022 Apr; 40(19):2781-2789. PubMed ID: 35370016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
    Furqan M; Chawla S; Majid M; Mazumdar S; Mahalwar G; Harmon E; Klein A
    Curr Cardiol Rep; 2022 Dec; 24(12):2031-2041. PubMed ID: 36441403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence of Myopericarditis and Myocardial Injury in Coronavirus Disease 2019 Vaccinated Subjects.
    Farahmand R; Trottier CA; Kannam JP; Ho KKL
    Am J Cardiol; 2022 Feb; 164():123-130. PubMed ID: 34852929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Catecholamines Are the Key Trigger of COVID-19 mRNA Vaccine-Induced Myocarditis: A Compelling Hypothesis Supported by Epidemiological, Anatomopathological, Molecular, and Physiological Findings.
    Cadegiani FA
    Cureus; 2022 Aug; 14(8):e27883. PubMed ID: 35971401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis.
    Alami A; Krewski D; Farhat N; Mattison D; Wilson K; Gravel CA; Farrell PJ; Crispo JAG; Haddad N; Perez-Lloret S; Villeneuve PJ
    BMJ Open; 2023 Jun; 13(6):e065687. PubMed ID: 37339840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.
    Su WJ; Liu YL; Chang CH; Lin YC; Huang WI; Wu LC; Chen SF; Lin YS; Hsieh YL; Yang CA; Lin CH; Chan KA; Lee PI; Chuang JH; Yang CH
    J Microbiol Immunol Infect; 2023 Jun; 56(3):558-565. PubMed ID: 36804307
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults: A Systematic Review and Meta-analysis.
    Yasuhara J; Masuda K; Aikawa T; Shirasu T; Takagi H; Lee S; Kuno T
    JAMA Pediatr; 2023 Jan; 177(1):42-52. PubMed ID: 36469338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methods, challenges and benefits of a health monitoring programme for Norwegian Olympic and Paralympic athletes: the road from London 2012 to Tokyo 2020.
    Clarsen B; Steffen K; Berge HM; Bendiksen F; Fossan B; Fredriksen H; Gjelsvik H; Haugvad L; Kjelsberg M; Ronsen O; Torgalsen T; Walløe A; Bahr R
    Br J Sports Med; 2021 Dec; 55(23):1342-1349. PubMed ID: 34039584
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emergency department activities at the Athletes' Village during the Tokyo 2020 Olympic and Paralympic Games.
    Kuroki N; Yagishita K; Shimizu K; Okuaki S; Doi Y; Arakawa Y; Nakano T; Akama T
    Acute Med Surg; 2023; 10(1):e905. PubMed ID: 38020491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis.
    Ling RR; Ramanathan K; Tan FL; Tai BC; Somani J; Fisher D; MacLaren G
    Lancet Respir Med; 2022 Jul; 10(7):679-688. PubMed ID: 35421376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activities of medical centers for athletes and spectators at cycling track events in the Tokyo 2020 Olympic and Paralympic Games.
    Yanagawa Y; Muto T; Shakagori M; Terakado A; Kumai T
    Acute Med Surg; 2022; 9(1):e728. PubMed ID: 35169484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report.
    Saeed S; Käsk L; Rajani R; Larsen TH
    Cardiology; 2022; 147(4):406-412. PubMed ID: 35104821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Periodic health evaluation in athletes competing in Tokyo 2020: from SARS-CoV-2 to Olympic medals.
    Squeo MR; Monosilio S; Gismondi A; Perrone M; Gregorace E; Lemme E; Di Gioia G; Mango R; Prosperi S; Spataro A; Maestrini V; Di Giacinto B; Pelliccia A
    BMJ Open Sport Exerc Med; 2023; 9(4):e001610. PubMed ID: 38046277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
    Nat Med; 2022 Feb; 28(2):410-422. PubMed ID: 34907393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
    Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
    Shenton P; Schrader S; Smith J; Alafaci A; Cox N; Taylor A; Hare J; Jones B; Crawford NW; Buttery JP; Cheng DR;
    Vaccine; 2024 Jan; 42(3):522-528. PubMed ID: 38154991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.